In early research of NK-based CAR against HIV, CD4-TCRζ CAR-modified NK cells were shown to effectively kill either NK-resistant tumor cells expressing the relevant ligand, gp120, or CD4+ T cells infected with HIV in vitro (Tran et al., 1995). Here, CD4 is linked to neoplasm.